Approval · Notice of Compliance 31141 · 2023
JULUCA: Notice of Compliance 31141
Issued July 6, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31141
- Date
- July 6, 2023
- Company
- Viiv Healthcare UlcMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Removal of the information related to the risk of sexual Human Immunodeficiency Virus-1 (HIV-1) transmission from the Product Monograph (PM). PM update to the master template
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JULUCA | Not yet assigned | — |
Medicinal ingredients
- RILPIVIRINE HYDROCHLORIDE 25 MG per TAB
- DOLUTEGRAVIR SODIUM 50 MG per TAB